Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Precigen, Inc.
Restructuring Edition: Impel eliminated R&D spending earlier this year to focus on Trudhesa commercialization, but is examining all options, including bankruptcy, as its funding runs out. Also, Alaunos, BioXcel and others announce job cuts and strategic shifts during second quarter updates.
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
The new collaboration announced 17 August is worth up to $475m in near-term upfront payments plus undisclosed milestone fees and royalties up to 24%.
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- ActoBio Therapeutics, Inc.
- ActoGeniX N.V.
- Exemplar Genetics
- GenVec, Inc.
- Immunologix, Inc.
- Intrexon ActoBiotics Division
- Intrexon Corporation (XON)
- Intrexon Health
- Intrexon T1D Partners, LLC (Joint Venture)
- MediStem Inc.
- MBP Titan LLC
- Trans Ova Genetics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.